Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study

Canadian study (n=327) provides data on antibody titres after homologous& heterologous dosing. Use of mRNA vaccine improved seroconversion after initial non mRNA vaccine comparable to homologous mRNA vaccination, and did not lead to immune-mediated inflammatory diseases flares
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news